Literature DB >> 17482972

Incident diabetes in clinical trials of antihypertensive drugs.

Simon Kh Lam1, Andrew Owen2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17482972     DOI： 10.1016/S0140-6736(07)60697-7

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  11 in total

1.  Low dose of hydrochlorothiazide, in combination with angiotensin receptor blocker, reduces blood pressure effectively without adverse effect on glucose and lipid profiles.

Authors:  Wakaya Fujiwara; Hideo Izawa; Gen Ukai; Hiroatsu Yokoi; Daisuke Mukaide; Kohsuke Kinoshita; Shin-ichiro Morimoto; Junichi Ishii; Yukio Ozaki; Masanori Nomura
Journal:  Heart Vessels       Date:  2012-03-25       Impact factor: 2.037

Review 2.  An overview of candesartan in clinical practice.

Authors:  Zeeshan Khawaja; Christopher S Wilcox
Journal:  Expert Rev Cardiovasc Ther       Date:  2011-08

3.  Gene expression in thiazide diuretic or statin users in relation to incident type 2 diabetes.

Authors:  Astrid Suchy-Dicey; Susan R Heckbert; Nicholas L Smith; Barbara McKnight; Jerome I Rotter; Yd Ida Chen; Bruce M Psaty; Daniel A Enquobahrie
Journal:  Int J Mol Epidemiol Genet       Date:  2014-02-17

4.  Ramipril-based versus diuretic-based antihypertensive primary treatment in patients with pre-diabetes (ADaPT) study.

Authors:  Walter Zidek; Joachim Schrader; Stephan Lüders; Stephan Matthaei; Christoph Hasslacher; Joachim Hoyer; Claudia Zemmrich; Peter Bramlage; Claus-Dieter Sturm; W Dieter Paar
Journal:  Cardiovasc Diabetol       Date:  2012-01-09       Impact factor: 9.951

Review 5.  Management of hypertension with fixed dose combinations of candesartan cilexetil and hydrochlorothiazide: patient perspectives and clinical utility.

Authors:  Thomas Mengden; Sakir Uen; Peter Bramlage
Journal:  Vasc Health Risk Manag       Date:  2009-12-29

6.  Oral antidiabetic treatment in type-2 diabetes in the elderly: balancing the need for glucose control and the risk of hypoglycemia.

Authors:  Peter Bramlage; Anselm K Gitt; Christiane Binz; Michael Krekler; Evelin Deeg; Diethelm Tschöpe
Journal:  Cardiovasc Diabetol       Date:  2012-10-06       Impact factor: 9.951

7.  Metabolic effects of an AT1-receptor blockade combined with HCTZ in cardiac risk patients: a non interventional study in primary care.

Authors:  Peter Bramlage; Eleonore Schönrock; Peter Odoj
Journal:  BMC Cardiovasc Disord       Date:  2008-11-10       Impact factor: 2.298

8.  First-line antihypertensive treatment in patients with pre-diabetes: rationale, design and baseline results of the ADaPT investigation.

Authors:  Walter Zidek; Joachim Schrader; Stephan Lüders; Stephan Matthaei; Christoph Hasslacher; Joachim Hoyer; Peter Bramlage; Claus-Dieter Sturm; W Dieter Paar
Journal:  Cardiovasc Diabetol       Date:  2008-07-24       Impact factor: 9.951

9.  Beta-blockers and the treatment of hypertension: it is time to move on.

Authors:  Charles Shey Wiysonge; Jimmy Volmink; Lionel H Opie
Journal:  Cardiovasc J Afr       Date:  2007 Nov-Dec       Impact factor: 1.167

10.  Differential renal effects of candesartan at high and ultra-high doses in diabetic mice-potential role of the ACE2/AT2R/Mas axis.

Authors:  Glaucia E Callera; Tayze T Antunes; Jose W Correa; Danielle Moorman; Alexey Gutsol; Ying He; Aurelie Nguyen Dinh Cat; Ana M Briones; Augusto C Montezano; Kevin D Burns; Rhian M Touyz
Journal:  Biosci Rep       Date:  2016-10-27       Impact factor: 3.840
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.